The Chemours Company $CC Shares Sold by Invesco Ltd.

Key Points

• Invesco Ltd. reduced its holdings in The Chemours Company by 11.6%, owning 901,898 shares after selling 118,103 shares during the first quarter.
• Chemours reported $1.62 billion in revenue for the quarter, exceeding expectations, with earnings per share of $0.58, higher than the consensus estimate of $0.46.
• The company has announced a quarterly dividend of $0.0875 per share, representing a 2.3% yield, with a negative dividend payout ratio of -12.50%.

Invesco Ltd. trimmed its position in The Chemours Company (NYSE:CC - Free Report) by 11.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 901,898 shares of the specialty chemicals company's stock after selling 118,103 shares during the quarter. Invesco Ltd. owned 0.60% of Chemours worth $12,203,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CC. FNY Investment Advisers LLC purchased a new stake in shares of Chemours in the 1st quarter worth $27,000. UMB Bank n.a. lifted its holdings in shares of Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 948 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Chemours by 170.7% during the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares during the last quarter. Itau Unibanco Holding S.A. grew its holdings in shares of Chemours by 39.3% during the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after buying an additional 1,003 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Chemours during the fourth quarter valued at $91,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Price Performance

CC stock traded up $0.31 during midday trading on Friday, reaching $15.38. The stock had a trading volume of 2,896,747 shares, compared to its average volume of 4,172,497. The company's fifty day simple moving average is $13.33 and its 200 day simple moving average is $12.85. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -5.49 and a beta of 1.61. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $22.38.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The company had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 15th will be given a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a yield of 2.3%. Chemours's payout ratio is currently -12.50%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CC shares. Barclays reduced their target price on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. UBS Group reduced their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Finally, Morgan Stanley lowered their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Chemours presently has a consensus rating of "Moderate Buy" and an average target price of $17.38.

Insiders Place Their Bets

In related news, insider Damian Gumpel acquired 7,822 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $9.95 per share, with a total value of $77,828.90. Following the completion of the transaction, the insider owned 131,701 shares of the company's stock, valued at $1,310,424.95. The trade was a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Denise Dignam bought 4,068 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $12.06 per share, with a total value of $49,060.08. Following the purchase, the chief executive officer owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 25,290 shares of company stock worth $250,437 in the last 90 days. Company insiders own 0.47% of the company's stock.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.